XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.2
Leases
12 Months Ended
Apr. 30, 2024
Leases [Abstract]  
Leases Leases
The Company accounts for its leases under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both an operating lease ROU asset and operating lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company has elected to apply the short-term lease exemption practical expedient for each class of underlying assets and excludes short-term leases having initial terms of 12 months or less. The Company recognizes rent expense on a straight-line basis over the lease term for these short-term leases. The Company has determined that no material embedded leases exist. Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
Operating Leases 

The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.8 million and $1.9 million for the years ended April 30, 2024 and 2023, respectively.

The Company leases the following facilities:
 
One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2026. The Company recognized $77,000 and $83,000 of rent expense relative to this lease for fiscal 2024 and 2023, respectively.
1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed the original lease in January 2017. The lease was amended to expand the premises and extend the expiration date in March 2020 and again in December 2020. The operating commencement date was August 11, 2017. This lease expires in February 2029. The Company recognized $1.7 million of rent expense for both fiscal 2024 and 2023.
VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed separate leases for its laboratory space and office space during fiscal 2022. During fiscal 2023, the Company executed a new lease to consolidate its office and laboratory space at a new nearby location in Italy. The lease expires October 31, 2028 and it replaces the previous two leases, which were terminated during fiscal 2023. The Company recognized $50,000 and $98,000 of rent expense associated with the leases in Italy for fiscal 2024 and 2023, respectively.

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):
April 30, 2024April 30, 2023
Operating lease right-of-use assets, net
6,252 7,318 
Current portion of operating lease liabilities
1,337 1,208 
Non-current portion of operating lease liabilities6,093 7,391 

As of April 30, 2024, the weighted average remaining operating lease term and the weighted average discount rate were 4.7 years and 5.88%, respectively. As of April 30, 2023, the weighted average remaining operating lease term and the weighted average discount rate were 5.7 years and 5.82%, respectively.

Future minimum lease payments for operating leases due each fiscal year as follows (in thousands):

2025$2,902 
20262,950 
20272,916 
20282,867 
20292,392 
Thereafter— 
 Total undiscounted liabilities 14,027 
Less: Imputed interest (6,597)
Present value of minimum lease payments$7,430 

The composition of total lease cost for the years ended April 30, 2024 and 2023 were as follows (in thousands):
Year Ended April 30
20242023
Operating lease costs$1,680 $1,566 
Financing lease costs:
   Amortization of leased assets146 135 
   Interest on lease liabilities 15 19 
Total lease costs$1,841 $1,720 

Refer to Note 4, Property and Equipment, for more information on financing leases.
Leases Leases
The Company accounts for its leases under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both an operating lease ROU asset and operating lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company has elected to apply the short-term lease exemption practical expedient for each class of underlying assets and excludes short-term leases having initial terms of 12 months or less. The Company recognizes rent expense on a straight-line basis over the lease term for these short-term leases. The Company has determined that no material embedded leases exist. Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
Operating Leases 

The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.8 million and $1.9 million for the years ended April 30, 2024 and 2023, respectively.

The Company leases the following facilities:
 
One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2026. The Company recognized $77,000 and $83,000 of rent expense relative to this lease for fiscal 2024 and 2023, respectively.
1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed the original lease in January 2017. The lease was amended to expand the premises and extend the expiration date in March 2020 and again in December 2020. The operating commencement date was August 11, 2017. This lease expires in February 2029. The Company recognized $1.7 million of rent expense for both fiscal 2024 and 2023.
VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed separate leases for its laboratory space and office space during fiscal 2022. During fiscal 2023, the Company executed a new lease to consolidate its office and laboratory space at a new nearby location in Italy. The lease expires October 31, 2028 and it replaces the previous two leases, which were terminated during fiscal 2023. The Company recognized $50,000 and $98,000 of rent expense associated with the leases in Italy for fiscal 2024 and 2023, respectively.

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):
April 30, 2024April 30, 2023
Operating lease right-of-use assets, net
6,252 7,318 
Current portion of operating lease liabilities
1,337 1,208 
Non-current portion of operating lease liabilities6,093 7,391 

As of April 30, 2024, the weighted average remaining operating lease term and the weighted average discount rate were 4.7 years and 5.88%, respectively. As of April 30, 2023, the weighted average remaining operating lease term and the weighted average discount rate were 5.7 years and 5.82%, respectively.

Future minimum lease payments for operating leases due each fiscal year as follows (in thousands):

2025$2,902 
20262,950 
20272,916 
20282,867 
20292,392 
Thereafter— 
 Total undiscounted liabilities 14,027 
Less: Imputed interest (6,597)
Present value of minimum lease payments$7,430 

The composition of total lease cost for the years ended April 30, 2024 and 2023 were as follows (in thousands):
Year Ended April 30
20242023
Operating lease costs$1,680 $1,566 
Financing lease costs:
   Amortization of leased assets146 135 
   Interest on lease liabilities 15 19 
Total lease costs$1,841 $1,720 

Refer to Note 4, Property and Equipment, for more information on financing leases.